Certara Inc (CERT) USD0.01
Certara, Inc. offers biosimulation software and technology. The Company develops medicines to patients using biosimulation software and technology for drug discovery and development. Biosimulation is a technology used to conduct virtual trials by using virtual patients to predict how drugs behave in different individuals. The Company delivers software products and technology-enabled services to customers to carry out biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. The Company’s regulatory science and market access software and services are supported by technologies including regulatory submissions software, natural language processing and Bayesian analytics. The Company has operations in the United States, Canada, Spain, Luxembourg, Portugal, United Kingdom, Germany, France, Netherlands, Denmark, Switzerland, Italy, Poland, Japan, Philippines, India, and Australia.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.